Strong order intake of $324 million reflecting a book-to-bill ratio of 1.23x should drive pick-up in revenue growth from Q2 with Mindtree now expecting to grow faster than industry average in FY20 vs earlier guidance for grow
UNOSUGEN, the brownfield expansion of the SUGEN plant, had signed up 278MW of its 382.5MW capacity with Distribution License (TPL-D) and the tariff on the same had been approved by CERC on a cost plus 15.5% RoE basis.
Cadila Healthcare’s (Cadila) reported Q4FY19 performance was broadly in line with our estimates, led by continued momentum in US sales. But the India business was muted with lower industry growth and restructuring exercise
Unless investors wish to give a significantly higher multiple for a long-term RoE potential (over 5 years), we expect the stock to see a suppressed multiple range of ~1-1.5x in the interim, leading to our TP of Rs 197, impl